Aviva Lev-Ari, PhD, RN
Director & Founder
Leaders in Pharmaceutical Business Intelligence (LPBI) Group
https://lnkd.in/eEyn69r
2025
Updated on 4/30/2025
Looking to the future, Aviva and her team’s intellectual property, encompassing their vast repository of scientific articles, e-books, images, podcasts, and conference proceedings, will serve as crucial training data for building a Multimodal Healthcare Foundation Model. This innovative approach, as outlined on https://pharmaceuticalintelligence.com/healthcare-foundation-model/, will leverage her team’s expert knowledge to enhance healthcare AI technologies, promising to revolutionize the way healthcare is delivered and understood. By integrating their extensive content into AI training datasets, Aviva and her team are poised to lead the next wave of advancements in healthcare, ensuring that their legacy continues to drive progress and innovation.
INTERACTIVE CHAT with Grok, created by xAI: LPBI Group’s Legacy and Biography of Aviva Lev-Ari, PhD, RN, Founder & Director
For DETAILED BIO by Perplexity.ai and Gemini 2.5 Pro (experimental), see
“Show Thinking” by AI Deep Research: The AI-generated Biography Description of Aviva Lev-Ari, PhD, RN, Founder of PharmaceuticalIntelligence.com by Perplexity.ai and by Google’s Gemini 2.5 Pro (experimental)
2024
Picture Source: San Diego, 12/30/2023
Picture updated on 2/6/2022
Aviva Lev-Ari, PhD, RN
Director & Founder
Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston Editor-in-Chief
http://pharmaceuticalintelligence.com
e-Mail: avivalev-ari@alum.berkeley.edu
(M) 617-775-0451
https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN
SkypeID: HarpPlayer83 LinkedIn Profile Twitter Profile
Roles on 1.0 LPBI Group’s present mission:
(1) Transfer of IP Ownership, and
(2) Team’s Exit as one human capital unit
- Sourcing IB(s) and or Acquirer(s)
- Shepard the Exit transaction completion
- Transition under the new ownership of LPBI IP portfolio of 10 asset classes and the team of experts
Roles on 2.0 LPBI Group’s New Strategies #1,2,3,4,5,6 for 1/2021 – 12/2025
Author: 2020=2021 VISION
https://pharmaceuticalintelligence.com/vision/
ACTIVITIES in 1Q 2021
- Pulling strings at the highest levels related to Exit – our life in 2.0 LPBI post first IB exploration.
- Works with Amanda on Article Views for 2020 data
- Continues to perfect the VISION for six strategies and four initiatives
https://pharmaceuticalintelligence.com/vision/
- The LIFE of Content Monetization Strategy – Designed the Data Architecture for the Blockchain IT infrastructure
- The LIFE of Medical Text Analysis Project
See all Updates in 1/2021, 12/2020, 11/2020 in 2020-2021 Vision
https://pharmaceuticalintelligence.com/vision/
- Wrote Recommendation Letters for Madison and Irina. Forthcoming Recommendation Letters: Danielle, Adina, Amanda
- The LIFE of 1.0 LPBI – continue to publish in the Journal and on Coronavirus Portal
- Will upload/PUBLISH in 1/2021 VOLUME #18 on Reproductive Genomics and Endocrinology [6+2+2+4+4 = 18]
- Interviewing NEW members of the External Business Relations Panel
- Running the Calendar & the Agenda for LPBI GLOBAL Monthly Zoom Meeting ~30 attendees – NEXT on 2/9/2021 and BEYOND in 2021
- Works with Robin to bring over 18 NEW Interns for IT Initiatives and for Medical Text Analysis on [6+2+2+4+4 = 18] Books.
- Preparing for submission ALL eTOCs for 18 Volumes for translation “English to Spanish” for a Pharmaceutical Publisher in Barcelona
- Working with Joel on a 10 Page PowerPoint and on Financials for NLP Products
- WILL CONDUCT on 3/30/2021 a ONE-on-ONE with All ACTIVE FIT members and with the INTERNS – we will look together on
- PERSONAL PORTALS (FIT members) and
- PERSONAL PAGES (Interns).
BIO
-
Professional Preparation
UNIVERSITY OF CALIFORNIA, BERKELEY
Activities and Societies: ASA, ORSA
Stanford University Graduate School of Business
Exchange Program with UC Berkeley 11 courses of MBA Program
Northeastern University
Biological and Biomedical Sciences, Four semesters, course load: 15 courses 2005
Northeastern University
Bouve College of Health Sciences, School of Nursing, Four semesters of Independent Research in Cardiovascular Pharmacotherapy with Prof. Paul Abourjaily
Activities and Societies: ANA, MARN
Hebrew University of Jerusalem
Urban Planning, Economic Geography
Activities and Societies: Israel Poets Association
HUGGIM – High School, Mount Carmel, Haifa, Israel
Baccalaureate in Economics and Political Sciences, 93/100
-
Appointments
- Scientific and Medical Affairs Chronological CV
- Technology Executive, Methodology and Decision Scientist, Functional CV
- Contributions to Design of Algorithm-based Decision Support Systems
- Technical Contributions in the Domain of Electronic Commerce Analytics: Aviva Lev-Ari, Ph.D.
- HealthCare Delivery – Long Term Post Acute Care Nursing Management CV
-
Nominations for Awards & Honors
- Nominee for 2020 Campanile Excellence in Achievement Award. This award recognizes an alumnus/a whose remarkable professional lifetime achievements reflect the excellence of a UC Berkeley education. Nominator: Sheila M. Puffer (UC, Berkeley, PhD’84).
https://awards.berkeley.edu/achievement-awards
The recipients will be formally presented with their awards at Berkeley Charter Gala on May 14, 2020.
- On 3/31/2018, Dr. Lev-Ari, PhD, RN was nominated for the 2018 Yidan Foundation Prize
Per request for supporting material, the following was submitted to the nominator, Prof. Marcus W. Feldman of Stanford University, Department of Biology.
Nomination for 2018 Yidan Prize, recognition in the field of medical education: development of curation methodologies for scientific content – 2018 Nominee, Aviva Lev-Ari, PhD, RN
- 8/17/2018, Dr. Lev-Ari, PhD, RN was contacted by the President elect of the Massachusetts Academy of Sciences (MAS), Prof. Katya Ravid of Boston University, School of Medicine, to join MAS in the role of Liaison to the Biotechnology and eScientific Publishing industries for the term of August 2018-July 2021. In the MAS, Dr. Lev-Ari serve as Board member, Fellow, and Advisor to the Governing Board.
- On 12/7/2018, Dr. Lev-Ari was nominated for 2019 Berkeley Alumna of the Year Achievement Award
2019 Awardees
https://awards.berkeley.edu/achievement-awards
-
Biography
On April 2012 had launched the Open Access Online Scientific Journal PharmaceuticalIntelligence.com – 1,811,456 Views and 5,908 scientific articles on 8/26/2020 since launch. It grew to 1,840,183 views and 5,940 scientific articles on 10/10/2020 ~~20,000 a month.
On December 31, 2020 the Open Access Online Scientific Journal PharmaceuticalIntelligence.com –
- 1,906,438 Views
- 7,524 Scientific Comments
- 5,978 articles
- 723 Research Categories
- 482,474 Views on Top Authors: Aviva Lev-Ari, PhD, RN
At 1.0 LPBI Group Aviva Lev-Ari, PhD, RN serves as
- Administrator of the platform and its Architect since 4/2012, the venture inception. # Views by eReaders of Administrator’s posts 466,589 on 10/10/2020, nearing 1/2 a Million e-Readers.
- Is the Launcher of the Website PharmaceuticalIntelligence.com
- Is the IP owner with agreements with each Expert, Author, Writer (EAW)
- Is the Editor-in-Chief of the
- Journal [com] and of
- the BioMed e-Series [https://pharmaceuticalintelligence.com/biomed-e-books/]
- Is the Co-Editor of several volumes in each series, except Series C: Cancer
- Is the Publisher of +3,400 of the 5,900 articles in the Journal
- Is the Developer of the Methodology of Curation for Pharmaceutics and Media top article 17,000 views, Several of Aviva’s articles fetched +10,000 views
- Is Developer of the Methodology of electronic Table of Contents (eTOCs) creation and was involved in the population of all eTOCs by Expert Editors that culled articles from the journal’s research categories to create ONE of a kind an eTOCs for each volume [except Series C: Cancer]
- Is Developer of the Methodology of Real Time Press Coverage of Top Biotech Conferences using social media and the ONE key stroke method for generation of the conference’s eProceedings.
- Is The Producer of 60 of the 70 Conference eProceedings in the venture’s Archive of Press Coverage of Biotech and Medical Conferences
- Lev-Ari is the creator of THREE intellectual property asset classes in Media & Healthcare (pharmaceutical, medicine, medical devices & diagnostics, bioinformatics). The three archives are ready for Text Analysis & Text Mining by AI, ML and NLP algorithms
- The three archives consist of the following IP assets:
LPBI Journal:
Open Access Online Scientific Journal PharmaceuticalIntelligence.com
- A collection of +5,900 scientific articles +1.8Million eReaders, and
- The Journal Ontology of +700 categories of Research
Sixteen volumes of Medical Books in Five specialties:
Series A: Cardiovascular – 6 volumes, BUNDLED BY AMAZON.COM INTO A SIX-VOLUME SERIES FOR $515
Series B: Genomics – 2 volumes
Series C: Cancer – 2 volumes
Series D: Immune system & Infectious Diseases – 3 volumes
Series E: Precision Medicine – 4 volumes
Biotech Conferences Press Coverage with Social Media:
https://pharmaceuticalintelligence.com/press-coverage/
- Lev-Ari is the Producer of Biotech & Medical Conference e-Proceedings:
Is the developer of the methodology for Real Time Press coverage with social media
The archive of 70 eProceeding documents was produced at 70 Biotech and Medical Conferences covered in Real Time during attendance. Each Conferences yielded on average 4 – 5 new curations in the Journal
Is the creator of the 30 Collections of Tweets she posted in real time at 60 of the 70 Biotech and Medical Conferences listed in
- Is the presenter of the Twitter Analytics of LPBI Group’s social media coverage of each conference by @pharma_BI and by @AVIVA1950
For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers]
CURRICULUM VITAE
- Scientific and Medical Affairs Chronological CV
- Technology Executive, Methodology and Decision Scientist, Functional CV
- Contributions to Design of Algorithm-based Decision Support Systems
- Technical Contributions in the Domain of Electronic Commerce Analytics: Aviva Lev-Ari, Ph.D.
- HealthCare Delivery – Long Term Post Acute Care Nursing Management CV
- Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence
- List of Invited Lectures, 1983 -2004
- List of Publications, 1983 – 2004
- List of Publications, 2006 – Present
- Cardiovascular Diseases and Pharmacological Therapy: Curations, 2006 – 4/2018
- MedTech & Medical Devices for Cardiovascular Repair – Curations
- Stem Cells and Cardiac Repair: Content Curation & Scientific Reporting
- Regulatory Affairs: Publications on FDA-related Issues – Aviva Lev-Ari, PhD, RN
- Cancer Research: Curations and Reporting
- Autobiographical Annotations: Tribute to My Professors
- Public Eulogy of Note: Prof. Allan Pred, University of California, Berkeley
- Public Eulogy of Note: Prof. David Hooson, University of California, Berkeley
- Photography and The Arts
PUBLICATIONS @ PharmaceuticalIntelligence.com
Books
Dr. Lev-Ari’s curations are on Cardiovascular Diseases – Six Volumes
-
Series A: e-Books on Cardiovascular Diseases – Six Volumes
- Cardiovascular Diseases, Volume One: Perspectives on Nitric Oxide in Disease Mechanisms. On comsince 6/21/2013 https://lnkd.in/8DANfq
- Cardiovascular Diseases, Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation. On comsince 11/30/2015 https://lnkd.in/ekbuNZ3
- Cardiovascular Diseases, Volume Three: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics. On comsince 11/29/2015 https://lnkd.in/ecp5mrA
- Cardiovascular Diseases, Volume Four: Regenerative and Translational Medicine: The Therapeutics Promise for Cardiovascular Diseases. On comsince 12/26/2015 https://lnkd.in/dwqM3K3
- Cardiovascular Diseases, Volume Five: Pharmacological Agents in Treatment of Cardiovascular Diseases. On comsince 12/23/2018 https://lnkd.in/e3r87cQ
- Cardiovascular Diseases, Volume Six: Interventional Cardiology for Disease Diagnosis and Cardiac Surgery for Condition Treatment. On comsince 12/24/2018 https://lnkd.in/e_CTb4R
Editor-in-Chief
http://www.amazon.com/dp/B00DINFFYC
http://www.amazon.com/dp/B018Q5MCN8
http://www.amazon.com/dp/B018PNHJ84
http://www.amazon.com/dp/B018DHBUO6
http://www.amazon.com/dp/B013RVYR2K
http://www.amazon.com/dp/B012BB0ZF0
http://www.amazon.com/dp/B019UM909A
http://www.amazon.com/dp/B019VH97LU
http://www.amazon.com/dp/B071VQ6YYK
https://www.amazon.com/dp/B075CXHY1B
https://www.amazon.com/dp/B076HGB6MZ
https://www.amazon.com/dp/B078313281
https://www.amazon.com/dp/B078QVDV2W
https://www.amazon.com/dp/B07MGSFDWR
https://www.amazon.com/dp/B07MKHDBHF
https://www.amazon.com/dp/B08385KF87
https://www.amazon.com/dp/B0CQXL5MTW
COMPLETE LIST:
https://www.amazon.com/s?k=Aviva+Lev-Ari&i=digital-text&rh=n%3A133140011&ref=nb_sb_noss
2012pharmaceutical
sjwilliamspa